Jiangsu HengRui Medicine Co., Ltd.: Lung Neoplasms trials

The registry lists 26 Lung Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 9 are open to participants now and 1 have results posted.

Phase 1 7Phase 2 15Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingNCT07241767Phase 2
• A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT07232849Phase 2
• A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCRecruitingNCT06754930Phase 1/2
• A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06589778Phase 1/2
• Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerNot yet recruitingNCT05503888Phase 1/2
• Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05416775Phase 1/2
• A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
• The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.Enrolling by invitationNCT04691063Phase 3
• A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLCRecruitingNCT04316364Phase 3
• SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyCompletedNCT03417895Phase 2Results posted
• A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
• A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung CancerStatus unknownNCT04884009Phase 2
• A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04818333Phase 1/2
• A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCActive, not recruitingNCT04580498Phase 2
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer PatientsCompletedNCT04041011Phase 1
• A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCStatus unknownNCT03904823Phase 2
• Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)Status unknownNCT03711305Phase 3
• A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Phase 3
• A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedNCT03666728Phase 2
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
• A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
• A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02364362Phase 1
• A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
• Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Status unknownNCT02332512Phase 3
• A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung CancerCompletedNCT01270386Phase 2